Royal Bank Of Canada Point Biopharma Global Inc. Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$6.67 - $9.71 $74,457 - $108,392	11,163 Added 67.83%	27,621 $184,000
Q2 2023 Aug 14, 2023	BUY	$6.86 - $10.86 $31,240 - $49,456	4,554 Added 38.26%	16,458 $149,000
Q1 2023 May 15, 2023	SELL	$6.78 - $8.1 $102,127 - $122,010	-15,063 Reduced 55.86%	11,904 $86,000
Q4 2022 Feb 14, 2023	SELL	$5.72 - $9.78 $1.26 Million - $2.15 Million	-220,135 Reduced 89.09%	26,967 $196,000
Q3 2022 Nov 14, 2022	BUY	$7.24 - $10.31 $3,721 - $5,299	514 Added 0.21%	247,102 $1.91 Million
Q2 2022 Aug 15, 2022	SELL	$5.6 - $9.5 $1.7 Million - $2.88 Million	-302,871 Reduced 55.12%	246,588 $1.68 Million
Q1 2022 May 16, 2022	BUY	$5.46 - $8.13 $2.98 Million - $4.43 Million	545,356 Added 13291.64%	549,459 $4.38 Million
Q4 2021 Feb 14, 2022	BUY	$4.83 - $9.75 $5,327 - $10,754	1,103 Added 36.77%	4,103 $23,000
Q3 2021 Nov 15, 2021	BUY	$7.42 - $11.26 $22,260 - $33,780	3,000 New	3,000 $23,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.